Targeting Oncogenic Fusion Proteins in Hematologic Malignancies with RNAi
Oncogenic fusion proteins, resulting from chromosomal translocations, are hallmark drivers of many hematologic malignancies. These fusion proteins often function as aberrant transcription factors or kinases, promoting uncontrolled cell growth and survival. Targeting them is a promising therapeutic strategy.
RNA interference (RNAi) techniques, including siRNA and shRNA, enable selective silencing of fusion gene transcripts by designing RNA molecules that span fusion junctions, thus sparing normal gene counterparts. For example, BCR-ABL in chronic myeloid leukemia (CML) and PML-RARA in acute promyelocytic leukemia (APL) are prominent fusion targets.
Successful knockdown of these oncogenic drivers using RNAi can inhibit proliferation, induce apoptosis, and sensitize cells to chemotherapeutics. Delivery of RNAi agents into leukemia cells is typically achieved via electroporation or viral vectors.
Challenges include efficient delivery, avoiding immune activation, and minimizing off-target effects. Combining RNAi with small-molecule inhibitors or immunotherapies may improve treatment outcomes and overcome resistance.
This targeted gene silencing approach exemplifies precision medicine, aiming to disrupt specific molecular abnormalities driving blood cancers.
References: Altogen.com Altogenlabs.com